ReviewHandbook of clinical neurology2012
Machado-Joseph disease/spinocerebellar ataxia type 3.
Review in Handbook of clinical neurology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
104 citing papers in PubMed, 6 syntheses or guidelines pooled it, 174 citations in OpenAlex.
- Quantitative Ocular Motor / Vestibular Assessment in Patients with Spinocerebellar Ataxia Type 3 (SCA3, Machado Joseph Disease) - Systematic Review of the Literature.Cerebellum (London, England) · 2026Pooled it
- Deep Brain Stimulation for Cerebellar Ataxia: A Systematic Review on Indications, Targets and Outcomes.Cerebellum (London, England) · 2026Pooled it
- Magnetic resonance imaging for spinocerebellar ataxia: a bibliometric analysis based on web of science.Frontiers in neurology · 2025Pooled it
- Specific Biomarkers in Spinocerebellar Ataxia Type 3: A Systematic Review of Their Potential Uses in Disease Staging and Treatment Assessment.International journal of molecular sciences · 2024Pooled it
- Neurocognitive Changes in Spinocerebellar Ataxia Type 3: A Systematic Review with a Narrative Design.Cerebellum (London, England) · 2022Pooled it
- Magnetic Resonance Imaging and Its Clinical Correlation in Spinocerebellar Ataxia Type 3: A Systematic Review.Frontiers in neuroscience · 2022Pooled it
- Transcranial alternating current stimulation for treating spinocerebellar ataxia type 3: A randomized controlled trial.Cell reports. Medicine · 2025Trial
- Digital Balance Biomarkers and Interpretable Evaluation of Disease Severity in Spinocerebellar Ataxia Type 3.Annals of the New York Academy of Sciences · 2026Article
- Article
- Article
- Comprehensive Characterization of Clinical Phenotypes and CTG Repeat-Associated Manifestations in Spinocerebellar Ataxia Type 8.Cerebellum (London, England) · 2026Article
- Nocturnal polygraphy in neuromuscular disorders: is it a useful diagnostic tool?Arquivos de neuro-psiquiatria · 2026Article
- Remote Assessment of Ataxia Severity in SCA3 Across Multiple Centers and Time Points.Annals of clinical and translational neurology · 2026Observational
- JOSD1-mediated stabilization of SUFU controls pancreatic cancer progression.Cell death & disease · 2026Article
- Embryonic spinocerebellar ataxia type 37-associated AUUUC repeat RNA causes neurodevelopmental defects.Disease models & mechanisms · 2026Article
- Another common genetic ataxia in South Korea: Spinocerebellar ataxia 36.European journal of human genetics : EJHG · 2026Article
- Utilizing Extracellular Vesicles for Delivering Therapies in Neurodegenerative Disorders.Current drug delivery · 2026Review
- Interpretable machine learning for differentiating SCA3 and MSA-C using gait and postural features from wearable sensors.Journal of neuroengineering and rehabilitation · 2025Article
- Dysphagia linked to clinical phenotype and disease progression in spinocerebellar ataxia type 3.European journal of medical research · 2025Article
- Roots of Progress: Uncovering Cerebellar Ataxias Using iPSC Models.Biomedicines · 2025Review
44 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Machado-Joseph disease (MJD), also known as spinocerebellar ataxia type 3 (SCA3), may be the most common dominantly inherited ataxia in the world. Here I will review historical, clinical, neuropathological, genetic, and pathogenic features of MJD, and finish with a brief discussion of present, and possible future, treatment for this currently incurable disorder. Like many other dominantly inherited ataxias, MJD/SCA3 shows remarkable clinical heterogeneity, reflecting the underlying genetic defect: an unstable CAG trinucleotide repeat that varies in size among affected persons. This pathogenic repeat in MJD/SCA3 encodes an expanded tract of the amino acid glutamine in the disease protein, which is known as ataxin-3. MJD/SCA3 is one of nine identified polyglutamine neurodegenerative diseases which share features of pathogenesis centered on protein misfolding and accumulation. The specific properties of MJD/SCA3 and its disease protein are discussed in light of what is known about the entire class of polyglutamine diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.